Dihydromyricetin has been shown to ameliorate reductions in diastolic and systolic function and conduction abnormalities induced by diabetes by downregulating HMGB1 and inhibiting the phosphorylation of NF-κB p65 (50). Here, HMGB1 is linked to diabetes mellitus.